HIGH SCHOOL EDITION
Journal of Student Research
Volume 13 Issue 2 (2024)

Genetic Modulators of Prion-Like Protein Propagation in Alzheimer's Disease

Alaina Shinde

Edison High School, USA

ABSTRACT

Alzheimer's disease (AD) is a widespread neurodegenerative disorder with complex causes. Starting with a historical overview, this paper traces the foundational discoveries by Alois Alzheimer and subsequent research into the roles of Tau, beta-amyloid (Aß), and cellular prion protein (PrP^{c}) in AD progression. The familial aspect of AD is discussed, highlighting genetic mutations in key genes such as *APP*, *PSEN1*, *PSEN2*, *MAPT*, and *APOE*. Additionally, it explores epigenetic factors in familial AD and examines the prion-like behavior of Tau and Aß proteins. Potential therapeutic targets arising from these insights are considered, including *PRNP* manipulation and modulation of Tau and Aß behavior. A proposed stem cell therapy aims to target and counteract the pathological activities of Tau and Aß proteins through strategic genetic modifications, precise delivery to affected brain regions, and controlled release systems for sustained therapeutic effects. Ethical considerations and limitations in AD research are also addressed, emphasizing the importance of responsible research practices and equitable access to treatments. Through this exploration, the text underscores the ongoing efforts to unravel the complexities of AD and develop effective strategies for its management.

Introduction

Alzheimer's disease (AD) is a progressive neurodegenerative disease identified by the death of brain cells, initially observed in the frontotemporal lobes of the brain, characterized by symptoms such as impaired neuronal transmission, brain atrophy and consequent shrinkage. External manifestations of AD include dementia, involving memory loss and declining cognitive and social skills. Of the 50 million cases of dementia worldwide, 60-70% have been diagnosed as Alzheimer's (World Health Organization, 2023).

In 1906, Alois Alzheimer, a German clinical psychiatrist and neuropathologist, provided the first description of Alzheimer's disease as a 'peculiar severe disease process of the cerebral cortex' (Neundörfer, 2003). And while research has advanced greatly in the past century since Alzheimer's discovery of his namesake disease, exact causes of AD remain a mystery to this day. Brain scans of AD patients have so far revealed extracellular parenchymal and intraneuronal aggregates of proteins, primarily the beta-amyloid and Tau proteins, leading to the formation of amyloid-beta (Aß) plaques and neurofibrillary tangles (NFTs) respectively. Authors have also hypothesized that the onset of the disease could be related to prions, or prion-like polymorphisms of proteins, as observed in the case of Tau, Aß, and more loosely related as seen in other neurodegenerative diseases α-synuclein (Sakono & Zako, 2010), superoxide dismutase-1 (Berdyński et al., 2022), serum amyloid-A (Yu et al., 2013), and huntingtin.

Prions are misfolded proteins which have been identified as causative agents of transmissible spongiform encephalopathies (TSEs), such as Creutzfeldt-Jakob disease. TSEs are characterized by the misfolding of normal cellular prion proteins into an abnormal, infectious form. Prions multiply via the conformational conversion of normal cellular prion proteins (PrP^{c}) to the disease-causing (PrP^{Sc}) isoforms, rather than the conventional nucleic acid replication (Liu et al., 1999). Aberrant processing during polypeptide synthesis due to mutations in the prion protein gene dictate the specific abnormality of the neurons in the disorder. In the context

of AD, versions of Tau and Aß proteins are observed to adopt prion-like properties, causing them to spread through the brain to induce neurotoxicity. Thus, these proteins could be potential culprits for progression of the disease.

To further unravel the intricacies of AD and identify potential genetic factors contributing to its pathogenesis, researchers are delving into familial Alzheimer's disease (FAD) (Yagi et al., 2011). FAD, which constitutes a small percentage of Alzheimer's cases, is characterized by a strong genetic component. By investigating families with a history of early-onset Alzheimer's, scientists are examining genetic markers and mutations associated with FAD to pinpoint specific genetic identifiers.

By conducting comprehensive genetic analyses, researchers aim to identify specific genetic variations or mutations that may enhance susceptibility to prion-like processes in AD. This approach involves scrutinizing the genetic profiles of individuals affected by AD, particularly those with a familial predisposition, to discern patterns and variations that could play a role in the development and propagation of prion-like pathologies. Understanding the genetic landscape of Alzheimer's, especially in the context of FAD, holds the promise of uncovering key genetic markers or risk factors associated with prion-related mechanisms. Such insights could pave the way for targeted interventions, personalized treatment strategies, and the development of early diagnostic tools, offering a new frontier in the battle against Alzheimer's disease.

Familial Patterns of Alzheimer's Disease

AD exhibits a complex interplay of genetic and environmental factors, with a subset of cases demonstrating a clear familial pattern known as familial Alzheimer's disease. While FAD constitutes a relatively small percentage of overall Alzheimer's cases, its significance lies in the strong hereditary component observed within affected families. This hereditary nature suggests a genetic predisposition that contributes to the early onset and development of the disease.

FAD is characterized by the occurrence of Alzheimer's symptoms in multiple members of the same family across generations, often manifesting at an earlier age than sporadic cases. The identification of families with a history of early-onset Alzheimer's has become instrumental in genetic research aimed at unraveling the specific genetic markers and mutations associated with FAD. By studying these familial clusters, researchers aim to pinpoint the genetic factors that play a crucial role in the pathogenesis of Alzheimer's, providing valuable insights into the broader spectrum of the disease.

Genetics of FAD

Genetic analyses of families with FAD have revealed several mutations in key genes associated with the processing of amyloid precursor protein (APP), which is involved in the formation of beta-amyloid plaques. Mutations in genes such as *APP*, presenilin-1 (*PSEN1*), and presenilin-2 (*PSEN2*) have been linked to the early onset of Alzheimer's symptoms in affected individuals (Lanoiselée et al., 2017). These findings underscore the importance of investigating the molecular mechanisms governing the production and aggregation of beta-amyloid in the quest to understand familial patterns of Alzheimer's.

Moreover, the exploration of the apolipoprotein E (*APOE*) gene, particularly the APOE ε4 allele, has provided additional insights into the genetic underpinnings of Alzheimer's. The presence of the *APOE* ε4 allele is a well-established risk factor for both sporadic and familial forms of the disease, influencing not only age of onset but also disease progression. Studying the familial patterns of *APOE* variants contributes significantly to our understanding of the intricate genetic landscape that contributes to Alzheimer's disease, offering potential targets for therapeutic interventions and personalized treatment strategies (Liu et al., 2013).

Epigenetics of FAD

Epigenetics plays a crucial role in the pathogenesis of FAD, a subset of AD cases with a strong genetic component. Research indicates that epigenetic mechanisms, including DNA methylation and histone modifications, are intricately involved in the regulation of gene expression patterns implicated in FAD (Sharma et al., 2020). Dysregulation of these epigenetic processes can lead to aberrant expression of genes associated with Aβ accumulation, tau hyperphosphorylation, and neuronal dysfunction, hallmark features of FAD (Yu et al., 2019). Understanding the epigenetic landscape of FAD holds promise for uncovering novel therapeutic targets and interventions aimed at modulating disease progression.

In FAD, alterations in DNA methylation patterns have been observed in genes associated with learning, memory, and neuroinflammation, contributing to the pathophysiological mechanisms underlying the disease. Studies have identified hypo- and hyper-methylation patterns in specific genomic regions of individuals with FAD, suggesting a complex interplay between epigenetic modifications and disease progression (Younesian et al., 2022). Additionally, the modulation of DNA methylation through dietary supplementation with methyl donors such as folate and vitamin B12 has shown promise in preclinical studies, highlighting the therapeutic potential of targeting epigenetic mechanisms in FAD management (Zhang, 2015).

Histone modifications, particularly histone acetylation and deacetylation, also play a critical role in FAD pathogenesis by regulating chromatin structure and gene transcription. Inhibitors of histone deacetylases (HDACs), such as valproic acid and vorinostat, have demonstrated beneficial effects in preclinical models of FAD by reducing Aβ plaque deposition and tau hyperphosphorylation (Younesian et al., 2022). Despite promising results, challenges such as toxicity and limited blood-brain barrier permeability remain significant hurdles in translating epigenetic-based therapies into clinical practice for FAD (Santana et al., 2023). Nevertheless, ongoing research efforts continue to elucidate the intricate interplay between epigenetic mechanisms and FAD pathology, offering new avenues for the development of targeted therapeutic interventions aimed at mitigating disease progression and improving patient outcomes.

Recently, Smith et al. (2018) conducted a study uncovering significant hypermethylation patterns across the HOXA gene cluster in the superior temporal gyrus and prefrontal cortex of AD patients. This finding signifies a potential epigenetic signature specific to AD pathogenesis, suggesting that aberrant DNA methylation in the HOXA region may contribute to the development or progression of the disease. The study underscores the importance of understanding epigenetic mechanisms in AD and highlights HOXA hypermethylation as a promising avenue for future research into diagnostic and therapeutic targets.

Cellular Prion Protein (PrP^c)

Prions, misfolded proteins known to cause transmissible spongiform encephalopathies, have been implicated in AD, particularly in the case of Tau, Aβ, and other proteins associated with neurodegenerative diseases. The prion protein (PrP) encoded by the *PRNP* gene is known for its role in prion diseases, but recent findings indicate its involvement in Aβ oligomer neurotoxicity. PrP, when binding with Aβ oligomers, activates the Fyn kinase, leading to tau hyperphosphorylation and synaptic dysfunction (Ritchie & Barria, 2021).

PrP^c, the normal isoform of PrP, exhibits diverse functions, including metal ion trafficking, cell adhesion, cell survival, and signal transduction. Considered a "double-faced gem," PrP^c, often viewed negatively due to its conversion into a neurotoxic isoform in prion diseases, has beneficial functions. PrP^c suppresses glutamate-mediated excitotoxicity, inhibits Aβ production by interacting with BACE1, and plays a role in metal ion trafficking. Constitutive proteolytic cleavage of PrP^c yields a soluble N-terminal fragment (N1) and a membrane-bound C-terminal fragment (C1), with N1 binding Aβ oligomers, offering protection by neutralizing their toxicity (Zhou, 2013).

Recent research highlights PrP^c as a cell surface receptor for Aβ oligomers (responsible for the synaptic dysfunction and cognitive deficit observed in AD), revealing a complex relationship between these proteins. As said above, two distinct binding sites for Aβ oligomers on PrP^c have been identified. The mechanism by which these oligomers exert their neurotoxic effect remains unknown. Recently, it was reported that Aβ oligomers bind to PrP^c with high affinity.

In a study conducted by Fluharty et al. (2013), it showed that N1, the main physiological cleavage fragment of PrP^c, is necessary and sufficient for binding early oligomeric intermediates during Aβ polymerization into amyloid fibrils. The ability of N1 to bind Aβ oligomers is influenced by positively charged residues in two sites (positions 23–31 and 95–105) and is dependent on the length of the sequence between them. N1 also suppresses Aβ oligomer toxicity in cultured murine hippocampal neurons, in a Caenorhabditis elegans-based assay, and in vivo in a mouse model of Aβ-induced memory dysfunction. This suggests that N1, or small peptides derived from it, could be potent inhibitors of Aβ oligomer toxicity and represent an entirely new class of therapeutic agents for AD.

Tau and Beta-Amyloid (Aß): Prion-Like Proteins in Alzheimer's Disease

AD involves misfolded Aβ and tau proteins with prion-like behavior, spreading through the brain. Aβ, working upstream of tau, induces tau oligomers' formation, suggesting a cross talk between the two prions.

Tau, a microtubule-associated protein predominantly found in neurons, plays a pivotal role in stabilizing microtubules, which are essential for the structural integrity and transport within nerve cells. However, in AD, Tau undergoes abnormal phosphorylation, leading to its misfolding and aggregation into neurofibrillary tangles (NFTs). These tangles disrupt the normal functioning of neurons and are a hallmark pathological feature of Alzheimer's.

Beta-amyloid, on the other hand, is a peptide derived from the cleavage of amyloid precursor protein (APP). In a healthy brain, APP undergoes processing to produce Aß, which is then cleared away. In Alzheimer's, there is an accumulation of Aß peptides that aggregate to form plaques. These plaques are found in the spaces between nerve cells and are associated with the disruption of neuronal communication.

The prion-like properties exhibited by Tau and Aß in Alzheimer's disease present a fascinating and significant aspect of the neurodegenerative processes at play. Prions, originally identified in the context of transmissible spongiform encephalopathies (TSEs), are misfolded proteins capable of inducing the misfolding of their normal counterparts, spreading pathological changes throughout the brain. In the case of Alzheimer's, Tau and Aß have emerged as proteins capable of engaging in similar prion-like behavior, contributing to the progressive degeneration observed in affected individuals (Kellett & Hooper, 2009).

Tau, normally involved in stabilizing microtubules within neurons, undergoes abnormal phosphorylation in Alzheimer's disease, leading to its misfolding and aggregation into neurofibrillary tangles (NFTs). What makes Tau particularly intriguing is its ability to propagate pathology in a prion-like manner. Misfolded Tau has been shown to induce the misfolding of normal Tau proteins, leading to the spread of pathological Tau aggregates from cell to cell. This self-perpetuating cycle of templated misfolding contributes to the widespread distribution of NFTs throughout the brain, exacerbating neuronal dysfunction and loss.

Understanding Tau as a prion-like protein is significant for several reasons. Firstly, it sheds light on the mechanisms driving the progressive nature of Alzheimer's pathology. The ability of misfolded Tau to seed the misfolding of normal Tau proteins amplifies the impact, creating a self-sustaining cascade of neurotoxicity. Secondly, this prion-like behavior introduces the concept of transmissibility within the brain, as misfolded Tau can travel between cells, contributing to the spatial spread of pathology observed in Alzheimer's disease (Ashe & Aguzzi, 2013).

Beta-amyloid, derived from the cleavage of amyloid precursor protein (APP), aggregates into plaques in Alzheimer's disease. Similar to Tau, Aß exhibits prion-like properties. Misfolded Aß can act as a seed,

prompting the misfolding of normal Aß peptides and promoting the aggregation of Aß into plaques. This templated misfolding of Aß contributes to the spatial progression of pathology within the brain, with Aß plaques accumulating in various regions. The significance of Aß as a prion-like protein lies in its role in the extracellular pathology of Alzheimer's. The spread of misfolded Aß between neurons not only contributes to the formation of plaques but also disrupts synaptic function and triggers inflammatory responses, further exacerbating neurodegeneration.

The prion-like properties of Tau and Aß offer a conceptual framework that links the molecular events within neurons to the progressive spread of pathology observed in Alzheimer's. This prion-like behavior introduces a new layer of complexity to our understanding of the disease's dynamics, emphasizing the interconnected nature of genetic predispositions, protein misfolding, and the spatial progression of neurodegeneration. Moreover, recognizing Tau and Aß as prion-like proteins has implications for potential therapeutic interventions. Targeting the mechanisms underlying the templated misfolding and spread of pathology could offer novel avenues for developing treatments aimed at disrupting these processes and slowing down the progression of Alzheimer's disease (Nussbaum et al., 2013).

Molecular and Genetic Convergence with Tau and Aß

Within the genetic patterns of FAD, the intricate relationship between genetic factors and the molecular underpinnings of the disease becomes increasingly apparent, particularly concerning the proteins Tau and beta-amyloid (Aß). Both of these proteins have been implicated in exhibiting prion-like properties, a phenomenon where misfolded proteins can induce the misfolding of their normal counterparts, spreading pathological changes throughout the brain (Tanzi et al., 1996).

In families with a history of early-onset Alzheimer's, where FAD is prevalent, genetic analyses have uncovered mutations in key genes associated with the processing of both Tau and Aß. Notably, mutations in the tau gene (*MAPT*) have been identified in certain familial cases, linking aberrations in Tau to the hereditary transmission of Alzheimer's symptoms. Tau, a microtubule-associated protein normally found in neurons, undergoes abnormal phosphorylation and misfolding in Alzheimer's, leading to the formation of neurofibrillary tangles (NFTs). In FAD, mutations in the *MAPT* gene may exacerbate Tau pathology, contributing to the prion-like spread of Tau aggregates in affected families (Strang et al., 2019).

Similarly, mutations in genes related to Aß production and processing, such as *APP*, *PSEN1*, and *PSEN2*, have been associated with FAD. These mutations influence the production of Aß, a peptide derived from the cleavage of APP, resulting in the accumulation of Aß plaques in the brain. Both Tau and Aß have been observed to adopt prion-like properties, allowing them to propagate within the brain tissue and induce neurotoxicity. This prion-like behavior involves the templated misfolding of normal Tau and Aß proteins by their pathological counterparts, creating a self-propagating cycle that contributes to the progressive degeneration seen in Alzheimer's.

Furthermore, the *APOE* gene, implicated in FAD and sporadic cases alike, connects the genetic landscape to the prion-like mechanisms of Tau and Aß. The *APOE* ε4 allele, a known risk factor for Alzheimer's, has been associated with increased Aß aggregation and decreased clearance. This genetic influence contributes to the prion-like spread of Aß pathology in affected individuals, further emphasizing the interconnected nature of genetic predispositions, protein misfolding, and the progression of Alzheimer's disease (Raulin et al., 2022).

In summary, the familial patterns of Alzheimer's disease provide a valuable lens through which to understand how genetic mutations in key genes, such as *MAPT*, *APP*, *PSEN1*, *PSEN2*, and *APOE*, contribute to the prion-like properties exhibited by Tau and Aß. The convergence of genetic factors and protein misfolding underscores the intricate web of events leading to the neurodegeneration characteristic of Alzheimer's, offering potential avenues for targeted interventions and therapeutic strategies.

Therapeutic Targets: *PRNP*, FAD Genetics, Tau, and Aβ

Understanding the interplay between PrP^c and Aβ provides a novel therapeutic avenue. Genetic ablation of PrP^c rescues Aβ oligomer neurotoxicity, suggesting it as a potential target. Antibodies blocking Aβ binding to PrP^c show promise in preventing synaptic toxicity. The prion-like activity of Aβ and tau underscores the importance of targeting specific Aβ assemblies. Strategies include inhibiting Aβ oligomerization, modulating *PRNP* expression, and enhancing α-cleavage to promote protective N1 production (Perry et al., 1995). Small molecules or antibodies interfering with Aβ-PrP^c interaction and downstream signaling pathways, including Fyn kinase, present potential therapeutic targets.

In the context of FAD, genetic studies have identified mutations in genes like *APP*, *PSEN1*, and *PSEN2*. These mutations influence Aβ production and aggregation. Targeting FAD genetics may unveil new avenues for intervention.

PRNP (Prion Protein Gene) as a Therapeutic Avenue

Understanding the intricate interplay between the prion protein (PrP) and Aβ offers a novel perspective for therapeutic intervention in Alzheimer's. Genetic ablation of the normal isoform of PrP (PrP^c) has demonstrated the potential to rescue Aβ oligomer neurotoxicity, suggesting PrP as a promising target. Antibodies designed to block the binding of Aβ to PrP^c have shown encouraging results in preventing synaptic toxicity (Younan et al., 2018). The prion-like activity exhibited by both Aβ and Tau underscores the importance of targeting specific Aβ assemblies. Therapeutic strategies include inhibiting Aβ oligomerization, modulating *PRNP* expression, and enhancing α-cleavage to promote the production of protective N1 fragments. Small molecules or antibodies that interfere with the interaction between Aβ and PrP^c, as well as downstream signaling pathways such as Fyn kinase, present promising avenues for therapeutic exploration (Nygaard, 2018).

FAD Genetics and Potential Interventions

In the context of FAD, characterized by a strong genetic component, genetic studies have unveiled mutations in key genes such as *APP*, *PSEN1*, and *PSEN2* (D'Argenio & Sarnataro, 2020). These mutations play a pivotal role in influencing the production and aggregation of Aβ. Understanding how these genetic mutations contribute to the prion-like properties of Tau and Aβ provides valuable insights into the disease's progression. By developing interventions that specifically address the genetic aberrations associated with FAD, researchers aim to disrupt the pathological processes at their roots, potentially altering the course of Alzheimer's disease.

Tau and Aβ: Prion-Like Proteins as Therapeutic Targets

Finally, Tau and Aβ, known for their prion-like behavior, have become focal points for therapeutic exploration. The misfolding and aggregation of Tau into NFTs and Aβ into plaques are hallmark features of Alzheimer's. Targeting the prion-like properties of these proteins presents an opportunity to intervene in the progressive degeneration observed in affected individuals. Strategies may include inhibiting Tau phosphorylation, disrupting the templated misfolding of Tau, and preventing the oligomerization of Aβ. By addressing the prion-like behavior of Tau and Aβ, therapeutic interventions aim to halt or slow down the spread of pathology, offering potential avenues for mitigating neurodegeneration in Alzheimer's disease.

In summary, targeting *PRNP*, FAD genetics, Tau, and Aβ provides a multifaceted approach to Alzheimer's disease therapy. By addressing key molecular and genetic factors associated with the disease, these targeted interventions aim to disrupt pathological processes, potentially offering innovative strategies for treating

or preventing the progression of Alzheimer's disease. Ongoing research in these areas holds promise for the development of effective and personalized therapeutic modalities to combat the complexities of this devastating neurodegenerative disorder.

Proposal: Stem Cell Therapy Targeting Tau and Aβ in Alzheimer's Disease

Stem cell therapy holds immense promise in the pursuit of innovative treatments for Alzheimer's disease by addressing the pathological role of Tau and Aβ proteins. This proposed approach involves the strategic utilization of different stem cell types, including neural stem cells (NSCs), mesenchymal stem cells (MSCs), and induced pluripotent stem cells (iPSCs). Each stem cell type is chosen for its unique properties, allowing for a multifaceted response to the complexities of AD pathology.

To tackle the aberrant activities of Tau and Aβ, genetic modifications within the stem cells are used. This includes the introduction of blockers against abnormal Tau and Aβ proteins, which could encompass the expression of anti-Tau or anti-Aβ antibodies or peptides. Simultaneously, activators promoting Tau phosphorylation or Aβ production are targeted for inhibition. These genetic modifications pave the way for stem cells to actively counteract the prion-like behaviors of Tau and Aβ (Kent et al., 2020).

A critical aspect of the proposed strategy is the engineering of stem cells for precise and targeted delivery. By enhancing homing mechanisms, we can guide the stem cells to specific brain regions affected by Alzheimer's pathology. This meticulous approach ensures that the therapeutic effects are concentrated where they are most needed. Moreover, optimizing the migration, survival, and integration of stem cells within the neural environment is crucial for the success of the therapy.

Stem cells, once appropriately modified and engineered, undergo neural differentiation. This process not only results in the generation of mature and functional neurons but also includes the differentiation of stem cells into astrocytes, promoting a supportive environment for neuronal health. Stereotactic implantation techniques are employed for the precise delivery of stem cells, and continuous monitoring through imaging techniques and biomarker analysis ensures the efficacy of the therapeutic intervention (Sivandzade & Cucullo, 2021).

To extend the duration of therapeutic action, the proposed approach involves controlled release systems. Encapsulation of stem cells in biomaterials allows for the sustained release of blockers or activators, maximizing their impact over time. Responsive systems, triggered by specific cues indicative of Alzheimer's pathology, add an extra layer of precision to the therapeutic strategy. The approach also advocates for a combinatorial strategy. Stem cell therapy is integrated with other treatment modalities, such as small molecule drugs or gene therapies, in a synergistic effort against Tau and Aβ pathology. This patient-specific combination approach tailors treatments based on individual genetic and molecular profiles (Mansour et al., 2023).

As researchers explore the potential of stem cell therapy in Alzheimer's, it must be emphasized that safety and ethical considerations are of utmost importance. Rigorous risk mitigation strategies are implemented to prevent unintended consequences of genetic modifications or stem cell therapies. Ethical oversight can be maintained in adherence to specified guidelines and regulatory standards governing stem cell research and therapy.

Limitations and Ethical Concerns

While the exploration of genetic and molecular factors in AD presents promising avenues for understanding and potentially treating the condition, it is essential to acknowledge the existing limitations and ethical considerations associated with such research.

One of the primary limitations lies in the complexity and multifactorial nature of AD. Despite significant advancements in genetic analyses and the identification of key players like Tau, Aß, and PrP^{c}, the intricate

web of interactions, overlapping pathways, and individual variabilities in disease progression remains a challenge to fully decipher. Genetic variations associated with FAD offer valuable insights, but their translation into effective therapeutic strategies demands a nuanced understanding of the broader genetic landscape and its interplay with environmental factors.

Ethical considerations also come to the forefront, particularly in the context of proposed therapeutic interventions. Stem cell therapy, while holding promise for addressing Tau and Aß pathology, raises ethical concerns related to genetic modifications, safety, and long-term consequences. Rigorous risk mitigation strategies and adherence to ethical guidelines are imperative to prevent unintended consequences of genetic alterations and ensure the safety and well-being of patients involved in clinical trials.

Moreover, the exploration of novel therapeutic targets, such as PrP^c, necessitates careful consideration of potential side effects, unintended consequences, and the balance between risk and benefit. Strategies involving Aβ and Tau modulation should be approached cautiously, considering the intricate balance these proteins maintain in normal cellular functions.

In the realm of FAD genetics, where mutations in key genes are associated with early-onset AD, the identification of potential therapeutic targets should be weighed against the challenges of gene-based interventions. Questions surrounding the specificity and long-term effects of such interventions must be thoroughly addressed to ensure the ethical implications of altering the genetic makeup.

Conclusion

The landscape of Alzheimer's disease research is evolving rapidly, driven by advancements in technology, genetic analyses, and our understanding of the intricate molecular and genetic underpinnings of the disease. As we reflect on the progress made and consider the future trajectory of AD research, it becomes evident that a multi-faceted and interdisciplinary approach is essential for unraveling the complexities associated with this devastating neurodegenerative disorder.

Technological innovations play a pivotal role in enhancing our understanding of AD at both cellular and clinical levels. Organoids, three-dimensional tissue cultures that mimic the structure and function of specific organs, including the brain, offer a unique platform for studying cellular interactions and disease mechanisms. The ability to generate brain organoids provides researchers with a more physiologically relevant model, allowing for the investigation of complex interactions between different cell types in a spatially organized manner.

Patient-derived cell lines have also emerged as valuable tools, providing insights into the genetic variations and molecular pathways associated with AD. By studying cells derived from individuals with FAD, researchers can gain a deeper understanding of the specific genetic mutations and their implications in disease progression. Moreover, these cell lines facilitate drug screening and the development of personalized therapeutic approaches tailored to individual genetic profiles.

Advanced brain imaging techniques, such as functional magnetic resonance imaging (fMRI) and positron emission tomography (PET), have revolutionized our ability to visualize and understand the functional and structural changes occurring in the brains of individuals with AD. These non-invasive imaging modalities enable the identification of early biomarkers, tracking disease progression, and assessing the efficacy of potential treatments. The integration of imaging data with genetic and molecular information provides a comprehensive view of the dynamic processes involved in AD (Xue et al., 2010).

However, amidst these technological advancements, ethical concerns and limitations persist. The use of advanced genetic manipulation techniques, such as CRISPR-Cas9, raises ethical questions related to the alteration of the human genome, necessitating stringent ethical oversight and guidelines (Ayanoglu et al., 2020). The creation and use of brain organoids also prompt ethical considerations, particularly regarding their level of

consciousness and the potential for unintended consequences. Moreover, the translation of findings from cellular and animal models to human clinical trials remains a challenge (Hyun et al., 2020). While these models offer valuable insights, their ability to fully capture the complexity of human brain function and disease progression is inherently limited. Bridging the gap between preclinical research and clinical applicability requires a cautious and iterative approach.

As we look to the future, collaborative efforts among scientists, clinicians, ethicists, and policymakers are crucial for addressing these challenges. The integration of technological advancements, ethical considerations, and a comprehensive understanding of AD's molecular and genetic basis holds the promise of ushering in a new era of targeted interventions, personalized treatments, and, ultimately, improved outcomes for individuals affected by Alzheimer's disease. The journey ahead requires a commitment to scientific rigor, ethical principles, and a relentless pursuit of knowledge to bring about meaningful advancements in the field of Alzheimer's research and care.

Acknowledgments

I would like to express my thanks and gratitude to my mentors, Dr. Jobin Varkey from the University of Southern California and Professor Virgel Torremocha. And to Gifted Gabber and Coach Jo, for their guidance and support in the development of this paper.

References

Ashe, K. H., & Aguzzi, A. (2013). Prions, prionoids and pathogenic proteins in Alzheimer disease. *Prion, 7*(1), 55–59. https://doi.org/10.4161/pri.23061

Ayanoglu, F. B., Elcin, A. E., & Elcin, Y. M. (2020). Bioethical Issues in Genome Editing by the CRISPR/Cas9 Technology. *Turkish Journal of Biology, 44*(2). https://doi.org/10.3906/biy-1912-52

Berdyński, M., Miszta, P., Safranow, K., Andersen, P. M., Morita, M., Filipek, S., Żekanowski, C., & Kuźma-Kozakiewicz, M. (2022). SOD1 mutations associated with amyotrophic lateral sclerosis analysis of variant severity. *Scientific Reports*, 12(1), 103. https://doi.org/10.1038/s41598-021-03891-8

D'Argenio, V., & Sarnataro, D. (2020). New Insights into the Molecular Bases of Familial Alzheimer's Disease. *Journal of Personalized Medicine, 10*(2). https://doi.org/10.3390/jpm10020026

Fluharty, B. R., Biasini, E., Stravalaci, M., Sclip, A., Diomede, L., Balducci, C., Vitola, P. L., Messa, M., Colombo, L., Forloni, G., Borsello, T., Gobbi, M., & Harris, D. A. (2013). An N-terminal Fragment of the Prion Protein Binds to Amyloid-β Oligomers and Inhibits Their Neurotoxicity in Vivo*. *Journal of Biological Chemistry, 288*(11), 7857–7866. https://doi.org/10.1074/jbc.M112.423954

Hyun, I., Scharf-Deering, J. C., & Lunshof, J. E. (2020). Ethical issues related to brain organoid research. *Brain Research, 1732*, 146653. https://doi.org/10.1016/j.brainres.2020.146653

Kellett, K. A. B., & Hooper, N. M. (2009). Prion protein and Alzheimer disease. *Prion, 3*(4), 190–194. https://doi.org/10.4161/pri.3.4.9980

Kent, S. A., Spires-Jones, T. L., & Durrant, C. S. (2020). The physiological roles of tau and Aβ: implications for Alzheimer's disease pathology and therapeutics. *Acta Neuropathologica.* https://doi.org/10.1007/s00401-020-02196-w

Lanoiselée, H.-M., Nicolas, G., Wallon, D., Rovelet-Lecrux, A., Lacour, M., Rousseau, S., Richard, A.-C., Pasquier, F., Rollin-Sillaire, A., Martinaud, O., Quillard-Muraine, M., de la Sayette, V., Boutoleau-Bretonniere, C., Etcharry-Bouyx, F., Chauviré, V., Sarazin, M., le Ber, I., Epelbaum, S., Jonveaux, T., & Rouaud, O. (2017). APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic

screening study of familial and sporadic cases. *PLoS Medicine, 14*(3). https://doi.org/10.1371/journal.pmed.1002270
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013). Apolipoprotein E and Alzheimer disease: risk, Mechanisms and Therapy. *Nature Reviews Neurology, 9*(2), 106–118. https://doi.org/10.1038/nrneurol.2012.263
Liu, H., Farr-Jones, S., Ulyanov, N. B., Llinás, M., Marqusee, S., Groth, D., Cohen, F. E., Prusiner, S. B., & Thomas Leroy James. (1999). *Solution Structure of Syrian Hamster Prion Protein rPrP(90−231)*. 38(17), 5362–5377. https://doi.org/10.1021/bi982878x
Mansour, A., Romani, M., Acharya, A. B., Rahman, B., Verron, E., & Badran, Z. (2023). Drug Delivery Systems in Regenerative Medicine: An Updated Review. *Pharmaceutics, 15*(2), 695. https://doi.org/10.3390/pharmaceutics15020695
Neundörfer, G. (2003). The discovery of Alzheimer's disease. *Dialogues in Clinical Neuroscience*, 5(1), 101. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181715/
Nussbaum, J. M., Seward, M. E., & Bloom, G. S. (2013). Alzheimer disease. *Prion, 7*(1), 14–19. https://doi.org/10.4161/pri.22118
Nygaard, H. B. (2018). Targeting Fyn Kinase in Alzheimer's Disease. *Biological Psychiatry, 83*(4), 369–376. https://doi.org/10.1016/j.biopsych.2017.06.004
Perry, R. T., Go, P., Harrell, L. E., & Acton, R. T. (1995). SSCP analysis and sequencing of the human prion protein gene (PRNP) detects two different 24 bp deletions in an atypical Alzheimer's disease family. *American Journal of Medical Genetics, 60*(1), 12–18. https://doi.org/10.1002/ajmg.1320600104
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022). ApoE in Alzheimer's disease: pathophysiology and therapeutic strategies. *Molecular Neurodegeneration, 17*(1). https://doi.org/10.1186/s13024-022-00574-4
Ritchie, D. L., & Barria, M. A. (2021). Prion Diseases: A Unique Transmissible Agent or a Model for Neurodegenerative Diseases? *Biomolecules, 11*(2), 207. https://doi.org/10.3390/biom11020207
Sakono, M., & Zako, T. (2010). Amyloid oligomers: formation and toxicity of Aβ oligomers. *FEBS Journal*, 277(6), 1348–1358. https://doi.org/10.1111/j.1742-4658.2010.07568.x
Santana, D. A., Smith, M. de A. C., & Chen, E. S. (2023). Histone Modifications in Alzheimer's Disease. *Genes, 14*(2), 347. https://doi.org/10.3390/genes14020347
Sharma, V. K., Mehta, V., & Singh, T. G. (2020). Alzheimer's Disorder: Epigenetic connection and associated risk factors. *Current Neuropharmacology, 18*(8). https://doi.org/10.2174/1570159X18666200128125641
Sivandzade, F., & Cucullo, L. (2021). Regenerative Stem Cell Therapy for Neurodegenerative Diseases: An Overview. *International Journal of Molecular Sciences, 22*(4), 2153. https://doi.org/10.3390/ijms22042153
Smith, R. G., Hannon, E., De Jager, P. L., Chibnik, L., Lott, S. J., Condliffe, D., Smith, A. R., Haroutunian, V., Troakes, C., Al-Sarraj, S., Bennett, D. A., Powell, J., Lovestone, S., Schalkwyk, L., Mill, J., & Lunnon, K. (2018). Elevated DNA methylation across a 48-kb region spanning the HOXA gene cluster is associated with Alzheimer's disease neuropathology. *Alzheimer's & Dementia, 14*(12), 1580–1588. https://doi.org/10.1016/j.jalz.2018.01.017
Strang, K. H., Golde, T. E., & Giasson, B. I. (2019). MAPT mutations, tauopathy, and mechanisms of neurodegeneration. *Laboratory Investigation, 99*(7), 912–928. https://doi.org/10.1038/s41374-019-0197-x
Tanzi, R. E., Kovacs, D. M., Kim, T.-W., Moir, R. D., Guenette, S. Y., & Wasco, W. (1996). REVIEWThe Gene Defects Responsible for Familial Alzheimer's Disease. *Neurobiology of Disease, 3*(3), 159–168. https://doi.org/10.1006/nbdi.1996.0016
Xue, G., Chen, C., Lu, Z.-L., & Dong, Q. (2010). Brain Imaging Techniques and Their Applications in Decision-Making Research. Acta Psychologica Sinica, 42(1), 120–137. https://doi.org/10.3724/sp.j.1041.2010.00120

Yagi, T., Ito, D., Okada, Y., Akamatsu, W., Nihei, Y., Yoshizaki, T., Yamanaka, S., Okano, H., & Suzuki, N. (2011). Modeling familial Alzheimer's disease with induced pluripotent stem cells. *Human Molecular Genetics, 20*(23), 4530–4539. https://doi.org/10.1093/hmg/ddr394

Younan, N. D., Chen, K.-F., Rose, R.-S., Crowther, D. C., & Viles, J. H. (2018). Prion protein stabilizes amyloid-β (Aβ) oligomers and enhances Aβ neurotoxicity in a Drosophila model of Alzheimer's disease. *Journal of Biological Chemistry, 293*(34), 13090–13099. https://doi.org/10.1074/jbc.ra118.003319

Younesian, S., Yousefi, A.-M., Momeny, M., Ghaffari, S. H., & Bashash, D. (2022). The DNA Methylation in Neurological Diseases. *Cells, 11*(21), 3439. https://doi.org/10.3390/cells11213439

Yu, C.-C., Jiang, T., Yang, A.-F., Du, Y.-J., Wu, M., & Kong, L.-H. (2019). Epigenetic Modulation on Tau Phosphorylation in Alzheimer's Disease. *Neural Plasticity*, *2019*, 1–12. https://doi.org/10.1155/2019/6856327

Yu, Y., Liu, J., Li, S.-Q., Peng, L., & Ye, R. D. (2013). Serum Amyloid A Differentially Activates Microglia and Astrocytes via the PI3K Pathway. *Journal of Alzheimer's Disease*, 38(1), 133–144. https://doi.org/10.3233/jad-130818

World Health Organization. (2023). Dementia. *World Health Organization*. https://www.who.int/news-room/fact-sheets/detail/dementia

Zhang, N. (2015). Epigenetic modulation of DNA methylation by nutrition and its mechanisms in animals. *Animal Nutrition, 1*(3), 144–151. https://doi.org/10.1016/j.aninu.2015.09.002

Zhou. (2013). Alzheimer's Disease and Prion Protein. *Intractable & Rare Diseases Research.* https://doi.org/10.5582/irdr.2013.v2.2.35